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Summary The posaconazole extended release tablet formulation was developed to improve bio-
availability relative to the oral suspension. Therapeutic drug monitoring has been
used to optimise posaconazole dosing to achieve a target trough level ≥0.7 lg ml1.
We retrospectively evaluated 28 patients with haematological malignancies who
received posaconazole tablets for antifungal prophylaxis. Posaconazole serum trough
levels were obtained 5 days after initiation of therapy. Mean trough level was
1.19  0.63 lg ml1, and 71% achieved a trough level ≥0.7 lg ml1. Diarrhoea
was associated with lower mean trough levels (0.65  0.08 lg ml1 vs.
1.31  0.13 lg ml1), P = 0.002. Mean trough levels were lower in patients
≥90 kg (0.74  0.09 lg ml1) vs. <90 kg (1.32  0.14 lg ml1), P = 0.002 and
in patients with body mass index (BMI) ≥30 (0.89  0.13 lg ml1) vs. BMI <30
(1.29  0.14 lg ml1), P = 0.05. Posaconazole delayed release tablets attain appro-
priate trough levels in most patients, but patients with a higher weight and those
experiencing diarrhoea are more likely to have lower levels.
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Introduction
Patients with acute myeloid leukaemia (AML) and
patients undergoing haematopoietic cell transplanta-
tion (HCT) are at high risk of developing invasive fun-
gal infections.1,2 Early antifungal treatment and
prevention are critical to improve survival of these
patients. Posaconazole is an antifungal triazole used
for prophylaxis in patients with AML and HCT
recipients.3,4 Use of posaconazole prophylaxis is one of
the few interventions that has improved overall sur-
vival in AML.3 Initially, this agent was available only
as a suspension that had rate-limiting absorption, was
hampered by inter- and intra-patient pharmacokinetic
variability, with a potential for suboptimal trough lev-
els and breakthrough fungal infections.5 Furthermore,
posaconazole suspension had to be administered with
food, which was another practical problem in a patient
population with frequent mucositis, nausea and vomit-
ing due to chemotherapy. Thus, therapeutic drug
monitoring of posaconazole has become a valuable
clinical tool to ensure that optimal drug levels are
achieved and efficacy is enhanced.
The Food and Drug Administration has recently
approved a delayed release posaconazole tablet formu-
lation that is reported to improve oral bioavailability.
The pharmacokinetics and safety of the new formula-
tion is based on healthy volunteer studies.6–8 This
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report describes our experience using the delayed
release posaconazole tablet for prophylaxis in high-risk
patients, with a focus on clinical parameters that may
impact serum posaconazole levels, and that could be
used as an aid to individualise dosing of this new
formulation.
Material and methods
This is a retrospective chart review study of patients
undergoing chemotherapy for AML and HCT recipients
who received delayed release posaconazole tablets for
prophylaxis from 1 February 2014 through 15 May
2014. Patients were eligible for the study if they
received posaconazole tablets at the recommended
dose of 300 mg twice daily on day 1 followed by
300 mg daily, and posaconazole steady state serum
trough levels were obtained on day 5. Patients were
excluded if they were already receiving posaconazole
or were being treated with a different dose of posaco-
nazole than that recommended by the package insert.
This study was approved by the University of Michi-
gan Healthcare System Institutional Review Board.
Posaconazole serum trough levels were measured
using high-performance liquid chromatography assay-
tandem mass spectrometry (performed at Mayo Clinic
Department of Laboratory Medicine and Pathology,
Rochester, MN). Therapeutic posaconazole serum
trough concentration was defined as ≥0.7 lg ml1 as
previously suggested for prophylactic antifungal effi-
cacy.9,10 Relevant demographics and patient charac-
teristics, including body mass index (BMI) and actual
body weight in kilograms, were obtained through
chart review. Clinical data, including diarrhoea, oral
intake, and concomitant use of proton-pump inhibitors
(PPI) or histamine-2 receptor antagonists (H2RAs)
were recorded.
Diarrhoea was defined as frequent and watery bowel
movement based on the Common Terminology Criteria
for Adverse Events definitions (CTCAE version 4.03:
any increase of ≥4 stools per day over baseline, faecal
incontinence, or moderate to severe increase in ost-
omy output compared to baseline).11
All statistical analyses were performed using Graph-
Pad Software (San Diego, CA). Statistical differences
between groups were determined using a Student’s t-
test with Welch’s correction and a one-way analysis of
variance (ANOVA) with a Turkey’s multiple comparison
test performed between groups for additional compari-
sons. Pearson correlation coefficient was calculated to
assess the relationship between BMI and posaconazole
serum trough levels and between actual body weight
and posaconazole serum trough levels. Quantitative
variables were reported as the number (percentage)
and continuous variables as the mean standard error
of the mean (SEM). A value of P < 0.05 was consid-
ered significant.
Results
A total of 28 patients (22 receiving chemotherapy for
AML and 6 HCT recipients) received the recommended
dose of posaconazole and had a posaconazole serum
trough level drawn on day 5 (Table 1). The day 5
mean serum trough level was 1.19  0.63 lg ml1
(range: 0.36–2.50 lg ml1). Seventy-one percent of
the patients achieved the target level of ≥0.7 lg ml1.
The effect of concomitant use of proton-pump inhib-
itors/histamine-2 receptor antagonists, diarrhoea, oral
intake and weight on posaconazole serum trough lev-
els at day 5 are reported in Table 2. Twenty-three of
28 patients were treated with either a PPI or H2RAs.
Mean trough levels among patients receiving these
agents was 1.11  0.12 lg ml1 vs. mean trough
levels of 1.62  0.32 lg ml1 among patients not
receiving either of these agents (P = 0.19).
Five patients who had diarrhoea documented during
the 5 days prior to obtaining the serum trough con-
centration had mean posaconazole trough level of
0.65  0.08 lg ml1 compared with a mean of
1.31  0.13 lg ml1 in patients without diarrhoea
(P = 0.002). Only 2 of 5 patients (40%) with diar-
rhoea achieved posaconazole trough concentrations
≥0.7 lg ml1 compared with 20 of 23 patients (86%)
who did not have diarrhoea.
Three of twenty-eight patients were fasting during
treatment with posaconazole extended release tablets.
Table 1 Patient demographics.
Demographic characteristics Patient data
Age, year, mean (range) 53 (19–77)
Male 16 (57%)
Race/ethnicity
Caucasian 23 (82%)
African American 2 (7%)
Hispanic 2 (7%)
Unknown 1 (4%)
Actual body weight, kg (mean, range) 79.8 (54.7–122.3)
<90 kg, n (%) 22 (78.5%)
≥90 kg, n (%) 6 (21.5%)
Body mass index1, kg/m2 (mean, range) 27 (20.4–36.9)
<30, n (%) 21 (75%)
≥30, n (%) 7 (25%)
1There were no patients with BMI below 20.
© 2015 Blackwell Verlag GmbH
Mycoses, 2015, 58, 432–436 433
Posaconazole tablet and serum trough levels
Posaconazole serum trough levels for these patients
were 0.72, 0.84 and 0.57 lg ml1; the last two
patients also had diarrhoea. The remaining 25
patients were not fasting and received posaconazole
without regard to food, achieving mean posaconazole
serum trough levels of 1.25  0.13 lg ml1. Three of
these 25 patients also had diarrhoea; posaconazole
trough levels were 0.4, 0.68 and 0.76 lg ml1
respectively.
We evaluated the effect of weight on posaconazole
trough concentration levels of all 28 patients included
in the study. We observed that mean posaconazole
trough concentrations were lower in patients who
weighed ≥90 kg (0.74  0.09 lg ml1) compared with
those who weighed <90 kg (1.32  0.14 lg ml1)
(P = 0.002). Similarly, mean posaconazole trough
levels were lower in patients with BMI ≥ 30
(0.89 0.13 lg ml1) compared with BMI < 30
(1.29 0.14 lg ml1), P = 0.05 (Fig. 1a).
Because of the effect of diarrhoea on posaconazole
trough levels noted above, we conducted a separate
analysis of the effect of weight on posaconazole trough
levels in the 23 patients who did not have diarrhoea.
Patients who weighed ≥90 kg had lower posaconazole
trough levels (mean 0.75  0.14 lg ml1) compared
Table 2 Effect of oral intake, concomitant use of proton-pump
inhibitors/histamine-2 receptor antagonists, diarrhoea, and
weight on posaconazole serum trough levels at day 5.
Risk factor
Patients,
n (%)
Posaconazole
trough level
(mean SD) P value
Oral intake Yes 25 (89%) 1.25  0.13 lg ml1 _
No 3 (11%)1 0.71  0.08 lg ml1
Concomitant
use of
PPI/H2RA2
Yes 23 (82%) 1.11  0.12 lg ml1 NS
No 5 (18%)3 1.62  0.32 lg ml1
Diarrhoea Yes 5 (82%) 0.65  0.08 lg ml1 0.002
No 23 (18%) 1.31  0.13 lg ml1
BMI4 <30 21 (75%) 1.29  0.14 lg ml1 0.05
≥30 7 (25%) 0.89  0.13 lg ml1
Actual body
weight (kg)4
<90 22 (78%) 1.32  0.14 lg ml1 0.002
≥90 6 (22%) 0.74  0.09 lg ml1
1All three patients had diarrhoea, no further analysis was possi-
ble after excluding these patients.
2PPI/H2RA, proton-pump inhibitors/histamine-2 receptor
antagonists.
3Only one of five patients who did not receive PPI/H2RA had
diarrhoea, posaconazole trough level for that patient was
0.84 lg ml1.
4After excluding patients with diarrhoea, patient weight and BMI
affected posaconazole levels significantly (see Fig. 1b).
(a)
(b)
Figure 1 Effect of body mass index and
actual body weight on posaconazole
serum trough level. (a) Distribution of
mean posaconazole serum trough levels
in all 28 patients based on actual body
weight (<90 vs. ≥90 kg) and body mass
index (<30 vs. ≥30). (b) Distribution of
mean posaconazole serum trough levels
when five patients who had diarrhoea
were excluded from the analysis. Patients
are divided based on actual body weight
(<90 vs. ≥90 kg) and body mass index
(<30 vs. ≥30).
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with those who weighed <90 kg (1.43  0.14 lg ml1)
(P = 0.006). In patients without diarrhoea, mean
posaconazole trough levels were lower in patients with
BMI ≥30 (0.93  0.15 lg ml1) compared with
BMI <30 (1.45  0.16 lg ml1), (P = 0.03) (Fig. 1b).
Scatterplots presented in Fig. 2 summarise the distri-
bution of body weight and BMI in the patient population
and the relationship with posaconazole serum trough
levels. Patients who had higher body weight (≥90 kg)
and higher BMI (≥30) had lower posaconazole serum
trough levels (correlation coefficient r = 0.4,
P = 0.035 and r = 0.3, P = 0.15 respectively)
(Fig. 2a). This correlation achieved greater significance
when patients with diarrhoea were excluded from the
analysis (correlation coefficient r = 0.59, P = 0.003
and r = 0.43, P = 0.04 respectively) (Fig. 2b).
Discussion
This report describes our experience using delayed
release posaconazole tablets for prophylaxis in high-
risk patients. Our findings suggest that this formula-
tion overcomes some of the expected variation in
serum trough levels that has been seen with posaco-
nazole solution.
Therapeutic drug monitoring of serum concentra-
tions is a surrogate for assessing patient exposure and
drug efficacy in the clinical setting.9 Although data
are conflicting, in clinical practice a target posaconaz-
ole trough concentration of ≥0.7 lg ml1 is used for
the prevention of invasive fungal infections.5,10,12–14
In our study, the majority (>70%) of patients attained
serum trough concentrations ≥0.7 lg ml1. However,
patients with BMI ≥30 or actual body weight ≥90 kg
were more likely to have suboptimal levels.
A cutoff of below and above 90 kg actual body
weight was chosen in this study as it was our anec-
dotal clinical observation that patients above this
threshold attained lower posaconazole serum concen-
trations. Indeed, it was this observation that led us to
conduct the present study. Similarly, we used BMI cut-
off of below and above 30 based on the World Health
Organization’s definition for obesity.15 Pathophysiolog-
ical changes seen in patients with higher BMI, such as
changes in blood volume, cardiac output, volume of
distribution, protein binding, and hepatic metabolism,
may alter the pharmacokinetics of posaconazole.16,17
Furthermore, we speculate that as posaconazole is a
lipophilic antifungal agent, it may distribute into the
excess adipose tissue of obese patients leaving less drug
available in the serum.18 Lastly, posaconazole is me-
tabolised via glucuronidation, which is increased in
obesity, potentially leading to increased metabolism,
elimination, and decreased exposure of posaconazole.16
Interestingly, in our study, the coefficient of correla-
tion was higher for the body weight than the BMI. As
the BMI is a function of body weight and height, it is
possible that patient body weight is the attributable
variable for the trough concentration. This may be a
reflection of the limitations of BMI. Indeed, BMI is
(a)
(b)
Figure 2 Correlation between body mass
index/actual body weight and posaconaz-
ole serum trough level. (a) Distribution of
actual body weight and body mass index
in all 28 patients and its correlation with
posaconazole serum trough levels. (b)
Distribution of actual body weight and
body mass index and the correlation with
posaconazole serum trough levels, after
excluding the five patients who had
diarrhoea.
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truly a measure of excess weight, rather than excess
adiposity. Age, sex, muscle mass can all skew the
accuracy of BMI. Whether total body weight, BMI or
both are relevant covariates for posaconazole serum
levels needs further investigation.
Patients with diarrhoea manifested suboptimal
trough concentrations. We speculate that lower
trough levels observed in these patients could be due
to gastrointestinal disruption and an increase in gas-
tric emptying, both resulting in less absorption.
Our study has several limitations. We studied a
small number of patients from a single centre. Ideally
tissue and not serum concentrations would have given
a better indication of posaconazole pharmacokinet-
ics.19 From this study, it is not known whether obese
patients attain high tissue concentrations despite lower
serum levels.
Clinicians should consider therapeutic drug monitor-
ing when using posaconazole, particularly in patients
with higher weight and BMI and those with diarrhoea.
Further studies are necessary to determine the optimal
dosing regimen in these patients.
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